Navigation Links
Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
Date:9/12/2007

EXTON, Pa., Sept. 12 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) will present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum at The Ritz-Carlton San Francisco on Tuesday, September 25, 2007.

Joseph W. Kaufmann, Kensey Nash's President & CEO, will deliver the Company's presentation, beginning at approximately 7:55 a.m. (PT). The presentation materials will be available on the company's website (http://www.kenseynash.com) beginning at 7:55 a.m. (PT) on Tuesday, September 25, 2007 and will remain on the website for approximately two weeks.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the endovascular, sports medicine and spine markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also commercialized a series of innovative products through its own direct endovascular sales force. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities including the Company's forecast of operating results for the first quarter and fiscal 2008. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, the Company's success in launching its endovascular products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling KNC related products in the marketplace, the impact of product recalls and other manufacturing issues, and competition from other technologies, among other important risks. For a more detailed discussion of these and other factors, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2018)... ... September 11, 2018 , ... Leading regenerative ... of Feline Practitioners Conference (AAFP) later this month. The company’s CEO ... therapy for the treatment of chronic kidney disease in felines at a poster ...
(Date:9/12/2018)... ... 12, 2018 , ... NDA Partners Chairman Carl Peck, MD, ... of Regulatory Affairs and Quality Systems at WellDoc, Inc., has joined the firm ... Quality Systems at WellDoc, Inc., she conducted quality control and supplier audits, led ...
(Date:9/7/2018)... ... 06, 2018 , ... The Discovery on Target (DOT) conference ... industry’s preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening (HTS) ... emerging targets in a quest to find new treatments for disease. , BellBrook ...
(Date:9/7/2018)... ... 2018 , ... Flagship Biosciences’ MuscleMap algorithm that supports therapeutic ... effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool ... the Archives of Pathology & Laboratory Medicine on August 31, 2018. Download the ...
Breaking Biology Technology:
(Date:8/29/2018)... ... August 28, 2018 , ... Johanna Dwyer, founder and Chief ... of excellence in the field of intellectual property, and named Daniela Sanchez as ... IP Award aims to encourage and support women in their pursuit of careers ...
(Date:8/29/2018)... ... August 29, 2018 , ... ... technology to identify specific chromosomal abnormalities using morphological assessment through artificial intelligence ... and Australia-based Life Whisperer suggests that artificial intelligence (AI) models, ...
(Date:8/26/2018)... ... August 24, 2018 , ... ... clinical diagnostic laboratories. However, this technology introduces many well-described challenges around data ... leads the South London NHS Genomic Medicine Centre. The Viapath Genetics Laboratories ...
Breaking Biology News(10 mins):